The management of acute venous thromboembolism in clinical practice – study rationale and protocol of the European PREFER in VTE Registry
Open Access
- 21 October 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in Thrombosis Journal
- Vol. 13 (1), 1-13
- https://doi.org/10.1186/s12959-015-0071-z
Abstract
Venous thromboembolism (VTE) is a major health problem, with over one million events every year in Europe. However, there is a paucity of data on the current management in real life, including factors influencing treatment pathways, patient satisfaction, quality of life (QoL), and utilization of health care resources and the corresponding costs. The PREFER in VTE registry has been designed to address this and to understand medical care and needs as well as potential gaps for improvement. The PREFER in VTE registry was a prospective, observational, multicenter study conducted in seven European countries including Austria, France Germany, Italy, Spain, Switzerland, and the UK to assess the characteristics and the management of patients with VTE, the use of health care resources, and to provide data to estimate the costs for 12 months treatment following a first-time and/or recurrent VTE diagnosed in hospitals or specialized or primary care centers. In addition, existing anticoagulant treatment patterns, patient pathways, clinical outcomes, treatment satisfaction, and health related QoL were documented. The centers were chosen to reflect the care environment in which patients with VTE are managed in each of the participating countries. Patients were eligible to be enrolled into the registry if they were at least 18 years old, had a symptomatic, objectively confirmed first time or recurrent acute VTE defined as either distal or proximal deep vein thrombosis, pulmonary embolism or both. After the baseline visit at the time of the acute VTE event, further follow-up documentations occurred at 1, 3, 6 and 12 months. Follow-up data was collected by either routinely scheduled visits or by telephone calls. Overall, 381 centers participated, which enrolled 3,545 patients during an observational period of 1 year. The PREFER in VTE registry will provide valuable insights into the characteristics of patients with VTE and their acute and mid-term management, as well as into drug utilization and the use of health care resources in acute first-time and/or recurrent VTE across Europe in clinical practice. Registered in DRKS register, ID number: DRKS00004795Keywords
This publication has 21 references indexed in Scilit:
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismNew England Journal of Medicine, 2012
- Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest, 2012
- New Antithrombotic Drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest, 2012
- The potential role of new oral anticoagulants in the prevention and treatment of thromboembolismPharmacology & Therapeutics, 2011
- Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Chest, 2008
- The worcester venous thromboembolism studyJournal of General Internal Medicine, 2006
- VEINES-QOL/Sym questionnaire was a reliable and valid disease-specific quality of life measure for deep venous thrombosisJournal of Clinical Epidemiology, 2006
- Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolismPublished by Wiley ,2006
- A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous ThromboembolismNew England Journal of Medicine, 1999
- The Duration of Oral Anticoagulant Therapy after a Second Episode of Venous ThromboembolismNew England Journal of Medicine, 1997